At the news
? NEUTRALIMPACT 4/10 S-3/A filed Apr 27, 2026 at 11:51 ET
PDS Biotechnology Corp filed an S-3/A shelf registration statement, authorizing the potential issuance of up to $200 million in securities, including common stock, preferred stock, debt securities, warrants, units, and rights. This filing updates market price information and removes a prior $20 million ATM offering, signaling the company's intent to access capital markets opportunistically in the future.
- PDSB filed an S-3/A shelf registration statement with an aggregate offering price of $200 million.
- The filing removes a prior $20 million ATM offering agreement.
- Proceeds are intended for product development, commercialization, and general corporate purposes.
- The company has a market cap of $50 million, making the $200 million shelf size significant at 400% of market cap.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access